{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:45:00Z","timestamp":1791387900393,"version":"4.3.3"},"reference-count":55,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Long-acting lipoglycopeptides (LGPs), such as dalbavancin and oritavancin, are semisynthetic antibiotics known for their strong effectiveness against a wide array of Gram-positive bacteria. This includes Staphylococcus aureus, both methicillin-sensitive (MSSA) and methicillin-resistant (MRSA) strains, coagulase-negative Staphylococci (CoNS), streptococci, and vancomycin-sensitive Enterococcus faecalis. A literature search was conducted on PubMed and on ClinicalTrials.gov to identify articles published until July 2023 investigating the use of oritavancin and dalbavancin in clinical practice. The review included case reports, case series, observational studies, and clinical studies. Although more consistent data are needed, LGPs seem to be a good alternative that may provide a quicker hospital discharge and reduce long-term intravenous access and therapy. This is attributed to their unique pharmacologic and pharmacokinetic characteristics. More quality data (i.e., number of patients treated with clinical success) are needed before clinicians may use these therapies more widely.<\/jats:p>","DOI":"10.3390\/pathogens13030189","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T11:50:07Z","timestamp":1708429807000},"page":"189","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["New Frontier on Antimicrobial Therapy: Long-Acting Lipoglycopeptides"],"prefix":"10.3390","volume":"13","author":[{"given":"Valentina","family":"Siciliano","sequence":"first","affiliation":[{"name":"Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Sangiorgi","sequence":"additional","affiliation":[{"name":"Dipartimento di Sicurezza e Bioetica, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4421-912X","authenticated-orcid":false,"given":"Pierluigi","family":"Del Vecchio","sequence":"additional","affiliation":[{"name":"Dipartimento di Sicurezza e Bioetica, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layla","family":"Vahedi","sequence":"additional","affiliation":[{"name":"Dipartimento di Sicurezza e Bioetica, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya Manuela","family":"Gross","sequence":"additional","affiliation":[{"name":"Dipartimento di Sicurezza e Bioetica, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Saviano","sequence":"additional","affiliation":[{"name":"Dipartimento di Emergenza Urgenza, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Ojetti","sequence":"additional","affiliation":[{"name":"Dipartimento di Emergenza Urgenza, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1517\/14656566.9.10.1745","article-title":"Dalbavancin: A lipoglycopeptide antibacterial for Gram-positive infections","volume":"9","author":"Roecker","year":"2008","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40121-016-0103-4","article-title":"Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections","volume":"5","author":"Brade","year":"2016","journal-title":"Infect. Dis. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"a026989","DOI":"10.1101\/cshperspect.a026989","article-title":"Approved Glycopeptide Antibacterial Drugs: Mechanism of Action and Resistance","volume":"6","author":"Zeng","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jmb.2008.01.031","article-title":"Oritavancin Exhibits Dual Mode of Action to Inhibit Cell-Wall Biosynthesis in Staphylococcus aureus","volume":"377","author":"Kim","year":"2008","journal-title":"J. Mol. Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.37201\/req\/s01.07.2021","article-title":"Dalbavancin","volume":"34","author":"Cuerda","year":"2021","journal-title":"Rev. Esp. Quimioter."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"106072","DOI":"10.1016\/j.ijantimicag.2020.106072","article-title":"Dalbavancin and telavancin in the treatment of infective endocarditis: A literature review","volume":"56","author":"Lampejo","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1093\/jac\/dky235","article-title":"Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015\u20132016","volume":"73","author":"Pfaller","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.jmb.2009.06.064","article-title":"Vancomycin and Oritavancin Have Different Modes of Action in Enterococcus faecium","volume":"392","author":"Patti","year":"2009","journal-title":"J. Mol. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.5001\/omj.2014.90","article-title":"VanA and VanB Positive Vancomycin-resistant Staphylococcus aureus Among Clinical Isolates in Shiraz, South of Iran","volume":"29","author":"Saadat","year":"2014","journal-title":"Oman Med. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1128\/AAC.43.8.1875","article-title":"Moderate-Level Resistance to Glycopeptide LY333328 Mediated by Genes of the vanA and vanB Clusters in Enterococci","volume":"43","author":"Arthur","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0378-1119(94)00851-I","article-title":"The vanZ gene of Tn1546 from enterococcus faecium BM4147 confers resistance to teicoplanin","volume":"154","author":"Arthur","year":"1995","journal-title":"Gene"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3390\/idr14020032","article-title":"Evaluating the Use of Dalbavancin for Off-Label Indications","volume":"14","author":"Taylor","year":"2022","journal-title":"Infect. Dis. Rep."},{"key":"ref_13","first-page":"250","article-title":"Dalbavancin in catheter-related bloodstream infections: A pilot study","volume":"31","author":"Venturini","year":"2023","journal-title":"Infez. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Lovatti, S., Tiecco, G., Mul\u00e9, A., Rossi, L., Sforza, A., Salvi, M., Signorini, L., Castelli, F., and Quiros-Roldan, E. (2023). Dalbavancin in Bone and Joint Infections: A Systematic Review. Pharmaceuticals, 16.","DOI":"10.3390\/ph16071005"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e0261420","DOI":"10.1128\/aac.02614-20","article-title":"New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides","volume":"66","author":"Tran","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1128\/AAC.50.3.994-1000.2006","article-title":"Pharmacokinetic-Pharmacodynamic Relationships Describing the Efficacy of Oritavancin in Patients with Staphylococcus aureus Bacteremia","volume":"50","author":"Bhavnani","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Texidor, W.M., Miller, M.A., Molina, K.C., Krsak, M., Calvert, B., Hart, C., Storer, M., and Fish, D.N. (2024). Oritavancin as sequential therapy for Gram-positive bloodstream infections. BMC Infect. Dis., 24.","DOI":"10.1186\/s12879-023-08725-8"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40801-020-00195-7","article-title":"Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retro-spective Study","volume":"7","author":"Chundi","year":"2020","journal-title":"Drugs Real World Outcomes"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/cid\/ciy279","article-title":"Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna","volume":"67","author":"Tobudic","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","article-title":"Dalbavancin in the treatment of different gram-positive infections: A real-life experience","volume":"51","author":"Bouza","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12941-019-0329-6","article-title":"DALBACEN cohort: Dalbavancin as consolidation therapy in patients with endocarditis and\/or bloodstream infection produced by gram-positive cocci","volume":"18","author":"Vinuesa","year":"2019","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"ofz028","DOI":"10.1093\/ofid\/ofz028","article-title":"Dalbavancin as Secondary Therapy for Serious Staphylococcus aureus Infections in a Vulnerable Patient Population","volume":"6","author":"Beieler","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ijid.2019.02.013","article-title":"Multicenter clinical experience of real life Dalbavancin use in gram-positive infections","volume":"81","author":"Wunsch","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ijantimicag.2019.08.006","article-title":"French national cohort of first use of dalbavancin: A high proportion of off-label use","volume":"54","author":"Dinh","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40121-019-0247-0","article-title":"Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections","volume":"8","author":"Bork","year":"2019","journal-title":"Infect. Dis. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"106210","DOI":"10.1016\/j.ijantimicag.2020.106210","article-title":"Comparison of dalbavancin to stand-ard-of-care for outpatient treatment of invasive Gram-positive infections","volume":"56","author":"Veve","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Evins, C., Lancaster, H., and Schnee, A.E. (2022). Successful use of dalbavancin in the treatment of gram positive blood stream infections: A case series. Ann. Clin. Microbiol. Antimicrob., 21.","DOI":"10.1186\/s12941-022-00507-5"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1017\/ash.2022.229","article-title":"Clinical outcomes following dalbavancin admin-istration in patients with barriers to outpatient parenteral antimicrobial therapy","volume":"2","author":"Tuan","year":"2022","journal-title":"Antimicrob. Steward. Healthc. Epidemiol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Lueking, R., Wei, W., Mang, N.S., Ortwine, J.K., and Meisner, J. (2023). Evaluation of Dalbavancin Use on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital. Microbiol. Spectr., 11.","DOI":"10.1128\/spectrum.02385-22"},{"key":"ref_30","first-page":"3654","article-title":"A Dalbavancin for Successful Treatment of Infective Endocarditis Caused by Enterococcus fae-calis","volume":"10","author":"Hertfelder","year":"2023","journal-title":"Eur. J. Case Rep. Intern. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1185602","DOI":"10.3389\/fphar.2023.1185602","article-title":"Dalbavancin as suppressive antibiotic therapy in patients with prosthetic infections: Efficacy and safety","volume":"14","year":"2023","journal-title":"Front. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Ioannou, P., Wolff, N., Mathioudaki, A., Spanias, C., Spernovasilis, N., and Kofteridis, D.P. (2023). Real-World Data Regarding Dal-bavancin Use before and during the COVID-19 Pandemic-A Single-Center Retrospective Study. Antibiotics, 12.","DOI":"10.3390\/antibiotics12071205"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e14068","DOI":"10.1111\/tid.14068","article-title":"Experience with dalbavancin for long-term antimicrobial suppression of left ventricular assist device infections","volume":"25","author":"Mansoor","year":"2023","journal-title":"Transpl. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"ofy331","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety","volume":"6","author":"Rappo","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.02280-18","article-title":"Safety and Efficacy of Prolonged Use of Dalbavancin in Bone and Joint Infections","volume":"63","author":"Morata","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diagmicrobio.2018.10.007","article-title":"Dalbavancin for the management of gram-positive oste-omyelitis: Effectiveness and potential utility","volume":"93","author":"Almangour","year":"2018","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s15010-019-01354-x","article-title":"Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection","volume":"47","author":"Tobudic","year":"2019","journal-title":"Infection"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Buz\u00f3n-Mart\u00edn, L., Zollner-Schwetz, I., Tobudic, S., Cercenado, E., and Lora-Tamayo, J. (2021). Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review. Antibiotics, 10.","DOI":"10.3390\/antibiotics10060656"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jgar.2021.03.026","article-title":"Dalbavancin treatment for prosthetic joint infections in real-life: A national cohort study and literature review","volume":"25","author":"Matt","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.02260-20","article-title":"Population Pharmacokinetics of Dalbavancin and Dosing Consideration for Optimal Treatment of Adult Patients with Staphylococcal Osteoarticular Infections","volume":"65","author":"Cojutti","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"ofab589","DOI":"10.1093\/ofid\/ofab589","article-title":"Effectiveness of Dalbavancin Compared with Standard of Care for the Treatment of Osteomyelitis: A Real-world Analysis","volume":"9","author":"Cain","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Mazzitelli, M., Gatti, M., Scaglione, V., Mengato, D., Trevenzoli, M., Sattin, A., Pea, F., and Cattelan, A.M. (2022). Off-Label Use of Dalbavancin for Sequential Treatment of Spondylodiscitis by Methicillin-Resistant Staphylococcus aureus: A Retrospective Single-Centre Experience. Antibiotics, 11.","DOI":"10.3390\/antibiotics11101377"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"S\u00f6derquist, B., Henningsson, T., and Stegger, M. (2023). Corynebacterium striatum Prosthetic Joint Infection Successfully Treated with Long-Term Dalbavancin. Microorganisms, 11.","DOI":"10.3390\/microorganisms11030550"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1007\/s00590-023-03609-8","article-title":"Effective use of a two-dose regimen of dalbavancin to treat prosthetic joint infections and spinal hardware infections","volume":"33","author":"Doub","year":"2023","journal-title":"Eur. J. Orthop. Surg. Traumatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"ofv156","DOI":"10.1093\/ofid\/ofv156","article-title":"Prolonged Use of Oritavancin for Vancomycin-Resistant Enter-ococcus faecium Prosthetic Valve Endocarditis","volume":"2","author":"Johnson","year":"2015","journal-title":"Open Forum. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40121-017-0156-z","article-title":"Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections","volume":"6","author":"Stewart","year":"2017","journal-title":"Infect. Dis. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/IPC.0000000000000517","article-title":"Oritavancin for the Treatment of Daptomycin Nonsus-ceptible Vancomycin-Resistant Enterococci Osteomyelitis","volume":"26","author":"Foster","year":"2017","journal-title":"Infect. Dis. Clin. Pract."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1002\/phar.1957","article-title":"Successful Treatment of Methicillin Susceptible Staphylococcus aureus Osteomyelitis with Oritavancin","volume":"37","author":"Delaportas","year":"2017","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/IPC.0000000000000599","article-title":"Successful Treatment of Methicillin-Resistant Staphylococcus aureus Vertebral Osteomyelitis with Outpatient Oritavancin Therapy","volume":"26","author":"Ruggero","year":"2018","journal-title":"Infect. Dis. Clin. Pract."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/phar.2057","article-title":"Multiple-Dose Oritavancin Evaluation in a Retrospective Cohort of Patients with Complicated Infections","volume":"38","author":"Schulz","year":"2018","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"ofx277","DOI":"10.1093\/ofid\/ofx277","article-title":"Long-Acting Lipoglycopeptides for Gram-Positive Bacteremia at the End of Life to Facilitate Hospice Care: A Report of 3 Cases","volume":"5","author":"Datta","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"ofz479","DOI":"10.1093\/ofid\/ofz479","article-title":"The CHROME Study, a Real-world Experience of Single- and Multiple-Dose Oritavancin for Treatment of Gram-Positive Infections","volume":"6","author":"Redell","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e02622-18","DOI":"10.1128\/AAC.02622-18","article-title":"Treatment of Multidrug-Resistant Vancomy-cin-Resistant Enterococcus faecium Hardware-Associated Vertebral Osteomyelitis with Oritavancin plus Ampicillin","volume":"63","author":"Dahesh","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ijantimicag.2018.11.023","article-title":"Treatment of chronic osteomyelitis with multidose oritavancin: A case series and literature review","volume":"53","author":"Chastain","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40801-020-00192-w","article-title":"Clinical Outcomes and Economic Impact of Oritavancin for Gram-Positive Infections: A Single Academic Medical Center Health System Experience","volume":"7","author":"Brownell","year":"2020","journal-title":"Drugs Real World Outcomes"}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/13\/3\/189\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:01:58Z","timestamp":1760104918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/13\/3\/189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,20]]},"references-count":55,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["pathogens13030189"],"URL":"https:\/\/doi.org\/10.3390\/pathogens13030189","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,20]]}}}